Literature DB >> 31526103

Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice.

Hannah Kohler1, Soeren Latteyer1, Georg Sebastian Hönes1, Sarah Theurer2, Xiao-Hui Liao3, Sandra Christoph4, Denise Zwanziger1, Johannes H Schulte5, Jukka Kero6,7, Hendrik Undeutsch7, Samuel Refetoff3,8,9, Kurt W Schmid2, Dagmar Führer1, Lars C Moeller1.   

Abstract

Background: Radioiodine refractory dedifferentiated thyroid cancer is a major clinical challenge. Anaplastic lymphoma kinase (ALK) mutations with increased ALK activity, especially fusion genes, have been suggested to promote thyroid carcinogenesis, leading to development of poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma. To determine the oncogenic potential of increased ALK activity in thyroid carcinogenesis in vivo, we studied mice with thyrocyte-specific expression of a constitutively active ALK mutant.
Methods: Mice carrying a Cre-activated allele of a constitutively active ALK mutant (F1174L) were crossed with mice expressing tamoxifen-inducible Cre recombinase (CreERT2) under the control of the thyroglobulin (Tg) gene promoter to achieve thyrocyte-specific expression of the ALK mutant (ALKF1174L mice). Survival, thyroid hormone serum concentration, and tumor development were recorded. Thyroids and lungs were studied histologically. To maintain euthyroidism despite dedifferentiation of the thyroid, a cohort was substituted with levothyroxine (LT4) through drinking water.
Results: ALKF1174L mice developed massively enlarged thyroids, which showed an early loss of normal follicular architecture 12 weeks after tamoxifen injection. A significant decrease in Tg and Nkx-2.1 expression as well as impaired thyroid hormone synthesis confirmed dedifferentiation. Histologically, the mice developed a carcinoma resembling human PDTC with a predominantly trabecular/solid growth pattern and an increased mitotic rate. The tumors showed extrathyroidal extension into the surrounding strap muscles and developed lung metastases. Median survival of ALKF1174L mice was significantly reduced to five months after tamoxifen injection. Reduced Tg expression and loss of follicular structure led to hypothyroidism with elevated thyrotropin (TSH). To test whether TSH stimulation played a role in thyroid carcinogenesis, we kept ALKF1174L mice euthyroid by LT4 substitution. These mice developed PDTC with identical histological features compared with hypothyroid mice, demonstrating that PDTC development was due to increased ALK activity and not dependent on TSH stimulation.
Conclusion: Expression of a constitutively activated ALK mutant in thyroids of mice leads to development of metastasizing thyroid cancer resembling human PDTC. These results demonstrate in vivo that increased ALK activity is a driver mechanism in thyroid carcinogenesis.

Entities:  

Keywords:  ALK; PDTC; anaplastic lymphoma kinase; poorly differentiated thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 31526103      PMCID: PMC8935483          DOI: 10.1089/thy.2018.0526

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  32 in total

1.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

2.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

3.  Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

Authors:  Avaniyapuram Kannan Murugan; Mingzhao Xing
Journal:  Cancer Res       Date:  2011-05-19       Impact factor: 12.701

Review 4.  American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Authors:  Bryan R Haugen; Anna M Sawka; Erik K Alexander; Keith C Bible; Patrizio Caturegli; Gerard M Doherty; Susan J Mandel; John C Morris; Aziza Nassar; Furio Pacini; Martin Schlumberger; Kathryn Schuff; Steven I Sherman; Hilary Somerset; Julie Ann Sosa; David L Steward; Leonard Wartofsky; Michelle D Williams
Journal:  Thyroid       Date:  2017-02-21       Impact factor: 6.568

5.  Outcomes in patients with poorly differentiated thyroid carcinoma.

Authors:  T Ibrahimpasic; R Ghossein; D L Carlson; I Nixon; F L Palmer; A R Shaha; S G Patel; R M Tuttle; J P Shah; I Ganly
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

6.  Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Authors:  Bryan R Haugen; Daniel W Bowles; Nikita Pozdeyev; Laurie M Gay; Ethan S Sokol; Ryan Hartmaier; Kelsi E Deaver; Stephanie Davis; Jena D French; Pierre Vanden Borre; Daniel V LaBarbera; Aik-Choon Tan; Rebecca E Schweppe; Lauren Fishbein; Jeffrey S Ross
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

7.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Authors:  Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle
Journal:  Thyroid       Date:  2012-11       Impact factor: 6.568

8.  Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

Authors:  J A Knauf; M A Sartor; M Medvedovic; E Lundsmith; M Ryder; M Salzano; Y E Nikiforov; T J Giordano; R A Ghossein; J A Fagin
Journal:  Oncogene       Date:  2011-03-07       Impact factor: 9.867

Review 9.  Differentiated Thyroid Cancer-Treatment: State of the Art.

Authors:  Benedikt Schmidbauer; Karin Menhart; Dirk Hellwig; Jirka Grosse
Journal:  Int J Mol Sci       Date:  2017-06-17       Impact factor: 5.923

10.  Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.

Authors:  Gaëlle Pérot; Isabelle Soubeyran; Agnès Ribeiro; Benjamin Bonhomme; Frédérique Savagner; Nathalie Boutet-Bouzamondo; Isabelle Hostein; Françoise Bonichon; Yann Godbert; Frédéric Chibon
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  5 in total

1.  Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.

Authors:  Mehtap Derya Aydemirli; Jaap D H van Eendenburg; Tom van Wezel; Jan Oosting; Willem E Corver; Ellen Kapiteijn; Hans Morreau
Journal:  Endocr Relat Cancer       Date:  2021-05-11       Impact factor: 5.678

2.  Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice.

Authors:  Ruoting Lin; Bowei Ma; Na Liu; Lu Zhang; Tiantian He; Xiongying Liu; Tongsheng Chen; Wenjuan Liu; Yongnan Liang; Tianfang Wang; Guoying Ni; Xiaosong Liu; Ning Yang; Jinhe Zhang; Jianwei Yuan
Journal:  Ann Nucl Med       Date:  2021-05-04       Impact factor: 2.668

Review 3.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

4.  Prediction Model of Pathologic Central Lymph Node Negativity in cN0 Papillary Thyroid Carcinoma.

Authors:  Xiujie Shu; Lingfeng Tang; Daixing Hu; Yuanyuan Wang; Ping Yu; Zhixin Yang; Chang Deng; Denghui Wang; Xinliang Su
Journal:  Front Oncol       Date:  2021-09-27       Impact factor: 6.244

5.  Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer.

Authors:  Liang Shi; Rui Duan; Qiong Jia; Wenyu Wu; Jianming Zhou; Shaohua Li; Hao Zhang; Xue Xue
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.